Diese Veröffentlichung wurde durch die finanzielle Unterstützung von Merck (Schweiz) AG ermöglicht.

Referenzen

De Stefano N et al. Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes. J. Neurol. Neurosurg. Psychiatry. 2014; 85(6): 647–53.
Comi G et al. Subcutaneous interferon β-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study. J. Neurol. Neurosurg. Psychiatry. 2017; 88(4): 285–94.
Freedman MS et al. Impact of the Presence of Gadolinium-Enhancing Lesions at Baseline on No Evidence of Disease Activity Status in Patients Treated with Subcutaneous Interferon beta-1a: A Post-hoc Analysis of REFLEXION. ECTRIMS-ACTRIMS 2017, 25-28 Oktober, Paris, France. Poster P1144.
PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998; 352(9139): 1498–504.
PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology. 2001; 56(12): 1628–36.
De Stefano N et al. Efficacy and safety of subcutaneous interferon β-1a in relapsing-remitting multiple sclerosis: further outcomes from the IMPROVE study. J. Neurol. Sci. 2012; 312(1–2): 97–101.
Kappos L et al. Factors influencing long-term outcomes in relapsing–remitting multiple sclerosis: PRISMS-15. J Neurol. Neurosurg. Psychiatry. 2015; 86(11): 1202–7.

a REFLEX: REbif FLEXible dosing in early MS

b REFLEXION: REbif FLEXible dosing in early MS extensION

c 7. Kongress des «European Committee on Treatment and Research in Multiple Sclerosis (ECTRIMS)» und «Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)», 25‒28 October 2017, Paris

d MRT: Magnetresonanztomographie

e CUA: Combined Unique Active

f DT: Delayed Treatment

g CDMS: Clinically Deﬁnite MS

h NEDA: No Evidence of Disease Activity

Weitere Informationen entnehmen Sie bitte der Fachinformation von Rebif^® (Interferon beta-1a) auf www.swissmedicinfo.ch.

IMPRESSUM

Redaktion:
H+O communications Ltd.
www.hando.ch

Kontakt:
Merck (Schweiz) AG
Healthcare
Chamerstrasse 174
6300 Zug
Switzerland

Tel.: +41417292222
Fax: +41417292200
E-Mail: info@merck.ch

CH/REB/1217/0080